Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065127 | 1.00 | KEAP1 (0.37) | KEAP1NFE2L2 | |
| SCHEMBL29924915 | 1.00 | KEAP1 (0.37) | KEAP1NFE2L2 | |
| SCHEMBL29795348 | 0.78 | ALDH1A1 (0.30) | — | |
| SCHEMBL24755330 | 0.78 | ALDH1A1 (0.30) | — | |
| SCHEMBL2541308 | 0.72 | HTT (0.32) | KEAP1NFE2L2 | |
| SCHEMBL29909463 | 0.72 | HTT (0.32) | KEAP1NFE2L2 | |
| SCHEMBL2175712 | 0.72 | GSK3A (0.31) | — | |
| SCHEMBL31732939 | 0.71 | — | — | |
| SCHEMBL29263382 | 0.71 | KEAP1 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL30577251 | 0.71 | KEAP1 (0.38) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190871-A1 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
| WO-2024088069-A1 | PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-115490689-B | Irreversible KRAS G12C Preparation and application of inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117263959-A | Preparation and application of aromatic KRAS mutant protein inhibitor | 药雅科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-115490689-A | Irreversible KRAS G12C Preparation of inhibitors and uses thereof | 药雅科技(上海)有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022193871-A1 | PREPARATION AND USE OF KRASG12D MUTANT PROTEIN INHIBITOR | 药雅科技(上海)有限公司 | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190871-A1 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, HRAS | KEAP1 224/4885NFE2L2 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.